Provided by Tiger Trade Technology Pte. Ltd.

Chemomab Therapeutics Ltd.

2.16
+0.09004.35%
Post-market: 2.12-0.0400-1.85%16:10 EDT
Volume:114.19K
Turnover:242.62K
Market Cap:15.83M
PE:-2.15
High:2.20
Open:2.06
Low:2.04
Close:2.07
52wk High:4.12
52wk Low:1.35
Shares:7.33M
Float Shares:6.14M
Volume Ratio:2.02
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0070
EPS(LYR):-1.4103
ROE:-82.17%
ROA:-46.27%
PB:1.82
PE(LYR):-1.53

Loading ...

Company Profile

Company Name:
Chemomab Therapeutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
3
Office Location:
Building C,10th Floor,10 Habarzel Street,Tel Aviv-Yafo,Israel
Zip Code:
6158101
Fax:
- -
Introduction:
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Directors

Name
Position
Adi Mor
Chief Executive Officer and Chief Scientific Officer and Director
Nissim Darvish
Chairman of the Board
Gwen Melincoff
Independent Director
Alan Moses
Director
Neil Cohen
Director

Shareholders

Name
Position
Adi Mor
Chief Executive Officer and Chief Scientific Officer and Director
Sigal Fattal
Chief Financial Officer
John Lawler
Chief Development Officer